Jason Napodano : On July 1, 2014, Pozen Inc ( POZN ) announced it had resubmitted the ..... and PA325/40 to the U.S. FDA. Pozen noted that the FDA is expected to ..... investors that on April 25, 2014, Pozen announced receipt of a complete response
Top gainers, as of 5:15 p.m.: PED +3.1% . POZN +2.8% . RSG +2.3% . POWR +2.0% . SHLM +2.0% . Top losers, as of 5:15 p.m.: CAMP -14.1% . TIME -9.0% . NSAM -4.5% . DXM -3.6% . TRQ -2.9% . Post your comment!
Pozen ( POZN +2.8% ) resubmits its NDA for PA8140/PA32540 to the FDA. The resubmission was necessary after the company received a CRL
Top gainers, as of 5:15 p.m.: FDO +5.3% . POZN +3.9% . SPIL +3.7% . CPE +2.5% . MY +2.4% . Top losers, as of 5:15 p.m.: NSR -9.1% . NADL -2.7% . CUR -2.4% . OTC:ENSV -1.7% . ANFI -1.7% . Post your comment!
By MacsJV : Orexigen Therapeutics ( OREX ) will announce on June 10th the FDA's decision on their weight loss drug Contrave . Recent events in the world of biotech trading provide supporting evidence for Orexigen's share price to run higher into their PDUFA. The IBB is an ETF composed of biotech ...
resembling a consensus on best practices for money funds. For example, earlier this week two former fund executives, Robert Pozen and Terry Hamacher, penned an Opinion article in The Wall Street Journal that stated support for the first of the SEC's two